Heidi Hunter - 30 May 2025 Form 4 Insider Report for IO Biotech, Inc. (IOBT)

Reporting relationship: Director
Issuer ticker: IOBT
Reported as of: 30 May 2025
Net transaction value: +$20,884
SEC form: 4
Accepted by SEC: 02 Jun 2025, 07:53:36 UTC
Prior SEC filing: 10 Jun 2024
Next SEC filing: 06 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Brian Burkavage, Attorney-in-Fact for Heidi Hunter

Key filing fact

Heidi Hunter filed Form 4 for IO Biotech, Inc. (IOBT) on 02 Jun 2025.

Key facts

This page summarizes Heidi Hunter's Form 4 filing for IO Biotech, Inc. (IOBT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Jun 2025, 07:53.

Change

Previous filing in this sequence was filed on 10 Jun 2024.
Current net transaction value: +$20,884.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001891841 Primary reporting owner

Hunter Heidi

Relationship: Director
Address: C/O IO BIOTECH, INC., OLE MAALOES VEJ 3, COPENHAGEN, DENMARK
Signature: /s/ Brian Burkavage, Attorney-in-Fact for Heidi Hunter
Signature date: 02 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IOBT transaction

Common Stock

Purchase

Transaction value: $20,884
Shares: +15,000
Change %
Price: $1.39
Shares after: 15,000
Date: 30 May 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The transaction was executed in multiple trades in prices ranging from $1.37 to $1.40, inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.